AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Cancer Biology & Medicine Article
PDF (386.6 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Perspective | Open Access

Less is more: patients with cervical cancer benefit from de-escalated chemotherapy plus immuno-targeted therapies

Bohao Zheng1,2,*, Dian Fan1,*, Shengtao Zhou1 ( )
Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education and State Key Laboratory of Biotherapy, West China Second Hospital, Sichuan University and Collaborative Innovation Center, Chengdu 610000, China
Wuxi School of Medicine, Jiangnan University, Wuxi 214000, China

*These authors contributed equally to this work.

Show Author Information

References

【1】
【1】
 
 
Crossref Google Scholar
Cancer Biology & Medicine
Volume 23 Issue 8,
August 2026
Pages 1051-1056
DOI: 10.20892/j.issn.2095-3941.2026.0139

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
Zheng B, Fan D, Zhou S. Less is more: patients with cervical cancer benefit from de-escalated chemotherapy plus immuno-targeted therapies. Cancer Biology & Medicine, 2026, 23(8): 1051-1056. https://doi.org/10.20892/j.issn.2095-3941.2026.0139

0

Views

0

Downloads

0

Crossref

0

Web of Science

0

Scopus
Received: 12 February 2026
Accepted: 19 May 2026
Published: 22 June 2026
©2026 The Authors.

Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)